For years, Africa grappled with a steady rise in mpox cases and recurring outbreaks, yet the disease remained largely overlooked by the global community. It was only when the virus reached Northern countries that mpox began to garner international attention. This long-standing neglect is evident in the sparse data on the disease, the minimal investment in research and development of medical countermeasures, delayed regulatory approvals, and stark inequities in access to these measures. In t...
All content for Health Equity in Focus is the property of Third World Network and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
For years, Africa grappled with a steady rise in mpox cases and recurring outbreaks, yet the disease remained largely overlooked by the global community. It was only when the virus reached Northern countries that mpox began to garner international attention. This long-standing neglect is evident in the sparse data on the disease, the minimal investment in research and development of medical countermeasures, delayed regulatory approvals, and stark inequities in access to these measures. In t...
In our inaugural episode, we explore the recent amendments to the International Health Regulations (IHR) and their implications for developing countries, particularly in light of the upcoming session of the Intergovernmental Negotiating Body (INB) negotiating a Pandemic Instrument. The IHR amendments represent a pivotal step towards recognizing the historical inequalities that have long plagued global health systems. Our guest, K.M. Gopakumar, a seasoned researcher and activist from the...
Health Equity in Focus
For years, Africa grappled with a steady rise in mpox cases and recurring outbreaks, yet the disease remained largely overlooked by the global community. It was only when the virus reached Northern countries that mpox began to garner international attention. This long-standing neglect is evident in the sparse data on the disease, the minimal investment in research and development of medical countermeasures, delayed regulatory approvals, and stark inequities in access to these measures. In t...
